C4 Therapeutics gets $35M from Betta Pharmaceuticals to develop and market NSCLC drug in China

Tyler Patchen

News Reporter

C4 Therapeutics, one of the early players in targeted protein degradation, has linked up with China-based Betta Pharmaceuticals to develop C4’s non-small cell lung cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

C4 Therapeutics gets $35M from Betta Pharmaceuticals to develop and market NSCLC drug in China

Tyler Patchen

News Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

China’s biotech market is staging a comeback that US biotech can only wish for

Ascletis posts puzzling Phase 1 update on obesity pill

Genentech vet launches ADC startup with $20M

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

C4 Ther­a­peu­tics gets $35M from Bet­ta Phar­ma­ceu­ti­cals to de­vel­op and mar­ket NSCLC drug in Chi­na

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

C4 Therapeutics gets $35M from Betta Pharmaceuticals to develop and market NSCLC drug in China